|
Real-time Estimate
Cboe BZX
12:55:41 2026-11-18 EST
|
5-day change | 1st Jan Change | ||
| 23.72 USD | -0.17% |
|
-12.47% | -22.05% |
Company Valuation: Rapport Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| Market Cap 1 | 648.9 | 1,446 | 1,408 | - | - |
| Change | - | 122.86% | -2.6% | - | - |
| Enterprise Value (EV) 1 | 343.6 | 955.5 | 742.6 | 876.4 | 800.6 |
| Change | - | 178.1% | -22.29% | 18.03% | -8.65% |
| P/E | -4.69x | -10.6x | -7.24x | -5.69x | -4.77x |
| PBR | - | 2.99x | 2.27x | 3.74x | 2.88x |
| PEG | -0.1x | 0.4x | -0.5x | -0.2x | -0.2x |
| Capitalization / Revenue | - | - | 70.4x | - | - |
| EV / Revenue | - | - | 37.1x | - | - |
| EV / EBITDA | -4.18x | -7.7x | -4.21x | -3.86x | -3.04x |
| EV / EBIT | -4.14x | -7.64x | -4.12x | -3.46x | -2.55x |
| EV / FCF | -5.11x | -10.8x | -6.4x | -4.65x | -3.53x |
| FCF Yield | -19.6% | -9.22% | -15.6% | -21.5% | -28.4% |
| Dividend per Share 2 | - | - | - | - | - |
| Rate of return | - | - | - | - | - |
| EPS 2 | -3.78 | -2.86 | -3.284 | -4.178 | -4.981 |
| Distribution rate | - | - | - | - | - |
| Net sales 1 | - | - | 20.01 | - | - |
| EBITDA 1 | -82.22 | -124.1 | -176.5 | -227.1 | -263.4 |
| EBIT 1 | -83.06 | -125.1 | -180.3 | -253.2 | -314.3 |
| Net income 1 | -78.31 | -111.5 | -164.6 | -240.4 | -304.9 |
| Net Debt 1 | -305.3 | -490.5 | -665.9 | -532.1 | -607.9 |
| Reference price 2 | 17.74 | 30.34 | 23.76 | 23.76 | 23.76 |
| Nbr of stocks (in thousands) | 36,576 | 47,661 | 59,280 | - | - |
| Announcement Date | 3/11/25 | 3/10/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| -7.24x | 37.1x | -4.21x | - | 1.41B | ||
| 17.32x | 6.64x | 12.72x | 1.72% | 66.37B | ||
| 31.83x | 8.5x | 28.08x | 0.07% | 58.86B | ||
| 38.41x | 6.84x | 20.46x | 0.85% | 55.22B | ||
| 44.35x | 6.2x | 29.52x | -.--% | 47.21B | ||
| 33.62x | 3.22x | 13.9x | -.--% | 42.45B | ||
| 35.98x | 8.9x | 23.21x | 0.36% | 36.44B | ||
| -19.28x | 55.7x | -21.11x | -.--% | 35.19B | ||
| 41.59x | 8.02x | 26.91x | -.--% | 32.66B | ||
| -74.36x | 14.09x | -75.73x | -.--% | 26.73B | ||
| Average | 14.22x | 15.52x | 5.37x | 0.33% | 40B | |
| Weighted average by Cap. | 21.51x | 11.73x | 11.33x | 0.44% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- RAPP Stock
- Valuation Rapport Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
















